Summary
22.58 -0.37(-1.61%)05/10/2024
Silence Therapeutics Plc (SLN)
Silence Therapeutics Plc (SLN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.46 | 1.69 | 4.27 | 5.60 | 126.94 | 244.81 | 0.00 | 14.05 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 22.24 | |
| Open | 21.68 | |
| High | 22.40 | |
| Low | 21.68 | |
| Volume | 79,247 | |
| Change | 0.32 | |
| Change % | 1.46 | |
| Avg Volume (20 Days) | 165,280 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 4.84 - 27.72 | |
| Price vs 52 Week High | -19.77% | |
| Price vs 52 Week Low | 359.50% | |
| Range | 2.58 | |
| Gap Up/Down | -0.99 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,013 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 4,996.60 | |
| Book Value | 0.5460 | |
| Earnings Per Share | -1.9260 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -1.9260 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -3.6817 | |
| Return on asset (TTM) | -0.2922 | |
| Return on equity (TTM) | -3.3374 | |
| Revenue TTM | 11,346,000 | |
| Revenue per share TTM | 0.3900 | |
| Quarterly Revenue Growth (YOY) | 0.5880 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,717,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 34.2237 | |
| Revenue Enterprise Value | 48.7619 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 29,928,200 | |
| Shares Float | 11,737,744 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.43 | |
| Institutions (%) | 6.54 | |
04/12 09:26 EST - Zacks Investment Research
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
04/11 12:24 EST - InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.
03/18 20:01 EST - InvestorPlace
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
03/13 10:01 EST - Seeking Alpha
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
02/28 09:31 EST - Zacks Investment Research
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
02/24 20:53 EST - Seeking Alpha
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look
Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected in 2024, which relate to the use of zerlasiran for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease. The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032; Targeting lipoprotein[a] for cardiovascular disease is an unmet need.
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look
Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected in 2024, which relate to the use of zerlasiran for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease. The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032; Targeting lipoprotein[a] for cardiovascular disease is an unmet need.
02/01 09:21 EST - Zacks Investment Research
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
01/11 13:32 EST - Zacks Investment Research
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Silence Therapeutics PLC Sponsored ADR (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Silence Therapeutics PLC Sponsored ADR (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
01/05 10:34 EST - Zacks Investment Research
Silence Therapeutics PLC Sponsored ADR (SLN) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Silence Therapeutics PLC Sponsored ADR (SLN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Silence Therapeutics PLC Sponsored ADR (SLN) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Silence Therapeutics PLC Sponsored ADR (SLN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
12/15 10:32 EST - Zacks Investment Research
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
07/14 19:15 EST - Seeking Alpha
Silence Therapeutics: No Reason For It To Fall So Much
SLN has fallen 65% after my last article. They produced good early data, they have decent cash, and there's no negative news. I can identify no reason for the stock to have declined so much.
Silence Therapeutics: No Reason For It To Fall So Much
SLN has fallen 65% after my last article. They produced good early data, they have decent cash, and there's no negative news. I can identify no reason for the stock to have declined so much.
05/09 08:24 EST - Zacks Investment Research
New Strong Sell Stocks for May 9th
ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.
New Strong Sell Stocks for May 9th
ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.
03/15 13:49 EST - Seeking Alpha
Silence Therapeutics plc (SLN) Q4 2022 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2022 Earnings Conference Call March 15, 2023 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda Hellums - Chief Financial Officer Giles Campion - Head of R&D Conference Call Participants Tom Shrader - BTIG Research Keay Nakae - Chardan Research Myles Minter - William Blair Research Operator Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast.
Silence Therapeutics plc (SLN) Q4 2022 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2022 Earnings Conference Call March 15, 2023 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda Hellums - Chief Financial Officer Giles Campion - Head of R&D Conference Call Participants Tom Shrader - BTIG Research Keay Nakae - Chardan Research Myles Minter - William Blair Research Operator Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast.
03/13 23:58 EST - Seeking Alpha
Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strategic collaborations, and favorable financial position.
Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strategic collaborations, and favorable financial position.
03/06 03:46 EST - Zacks Investment Research
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
01/18 10:33 EST - Zacks Investment Research
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
01/04 13:32 EST - Zacks Investment Research
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
01/03 07:00 EST - Business Wire
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. PT.
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. PT.
12/06 02:19 EST - Seeking Alpha
Silence Therapeutics: Excellent Data In A Cardiovascular Indication
SLN is a gene silencing therapy developer. SLN produced excellent data from its lead candidate.
Silence Therapeutics: Excellent Data In A Cardiovascular Indication
SLN is a gene silencing therapy developer. SLN produced excellent data from its lead candidate.
03/17 14:02 EST - Seeking Alpha
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript